AlzChem adjusts the forecast for fiscal year 2020 due to COVID-19
Trostberg, October 14, 2020 – Due to the continuing economic effects of the COVID-19 pandemic in individual target industries and regions, AlzChem Group AG adjusts its forecast for fiscal year 2020. The continued very positive development, especially for Bioselect® products, which are among other things an essential component of the COVID-19 test kits, cannot fully compensate for these effects.
Therefore, the company now expects to generate stable to slightly declining consolidated sales compared to the previous year (original forecast: slightly rising to sharply rising). A similar development can be expected for adjusted EBITDA (original forecast: stable to sharply rising).